Tests volrustomig after chemoradiation in women with locally advanced cervical cancer
Tests volrustomig, or a placebo, in women with advanced cervical cancer after chemoradiation.
Plain-language title generated from the registry record
Registry title: Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Key facts
- Where
- Oslo, Tromsoe, and Trondheim, NorwaySee the 3 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with high-risk locally advanced cervical cancer whose disease has not progressed after platinum-based chemoradiation (CCRT).
- Age
- At least 15 years old. Those under 18 must be at Tanner Stage III. Body weight over 35 kg (77 lb).
- Sex
- Female only.
- Disease stage
- FIGO 2018 stage IIIA to IVA cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma, with no sign of metastatic disease.
- Earlier treatment
- Must have had platinum-based CCRT and not progressed after it. No other prior or current treatment for cervical cancer. No prior immune-mediated therapy.
- Biomarker or test result
- A tumor sample must be provided to test PD-L1 expression.
Main reasons for not taking part
- Small cell (neuroendocrine) or mucinous cervical cancer
- Metastatic disease
- Organ or allogenic stem cell transplant
- Active or past autoimmune or inflammatory disorder, or active primary immunodeficiency
- Previous hysterectomy, or a hysterectomy planned as part of initial cervical cancer therapy
Read by machine on 11 November 2026.
Where in Norway
- Oslo University Hospital HFOslo, NorwayTaking people
- Universitetssykehuset Nord-Norge HFTromsoe, NorwayTaking people
- St. Olavs hospital HFTrondheim, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06079671EU 2023-504374-38-00
- Record updated
- 10 November 2026
- Original description
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Inclusion: For inclusion in the study, patients should fulfill the following criteria:; Female; Aged at least 15 years at the time of screening. Note: Participants < 18 years of age: physical changes should be aligned with Tanner Stage III; Body weight > 35 kg; Histologically documented FIGO 2018 Stage IIIA to IVA cervical adenocarcinoma, cervical squamous carcinoma, or cervical adenosquamous carcinoma, with no evidence of metastatic disease; Initial staging procedures performed no more than 56 days prior to the first dose of CCRT; Provision of FFPE tumor sample to assess the PD-L1 expression; Must not have progressed following CCRT, participants with persistent disease after definitive CCRT must not be amenable to other available therapies with curative intent; WHO/ECOG performance status of 0 or 1; duration of life expectancy of ≥ 12 weeks; Adequate organ and bone marrow function; Capable of providing signed informed consent.
Exclusion: History of active primary immunodeficiency or active or prior documented autoimmune or inflammatory disorders; History of another primary malignancy except for a) Malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease; Unresolved toxicities from previous CCRT except for irreversible toxicity that is not reasonably expected to be exacerbated; Prior history or presence of vesicovaginal, colovaginal, or rectovaginal fistula; Current or prior use of immunosuppressive medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication or chemotherapy premedication) or a single dose for palliative purpose (eg, pain control); c) Physiologic doses of oral corticosteroids, ie, not exceeding 10 mg/day of prednisone (or equivalent) in the preceding 14 days; Patients who have undergone a previous hysterectomy, including a supracervical hysterectomy, or will have a hysterectomy as part of their initial cervical cancer therapy; Any prior (besides prior CCRT) or concurrent treatment for cervical cancer; Major surgical procedures within 4 weeks prior to the first dose of the study intervention or still recovering from prior surgery; Exposure to immune mediated therapy prior to the study for any indication; Receipt of live attenuated vaccine within 30 days prior to the first dose of the study intervention; Diagnosis of small cell (neuroendocrine) or mucinous adenocarcinoma of cervical cancer; Evidence of metastatic disease; History of organ transplant or allogenic stem cell transplant; Uncontrolled intercurrent illness; History of anaphylaxis to any biologic therapy or vaccine; Participants with a known allergy or hypersensitivity to the study intervention, or any excipients of the study intervention; Patients should not enter the study if any of the following exclusion criteria are fulfilled:; Intent to administer a fertility-sparing treatment regimen.